0000000000050234

AUTHOR

Ferri C

showing 7 related works from this author

Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observationa…

2018

The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clar…

medicine.medical_specialtySettore MED/09 - Medicina InternaPrognosiEpidemiologyPopulationDiseaseHyperuricemia030204 cardiovascular system & hematologyRisk AssessmentCardiovascular disease; Epidemiology; Uric acid; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid; Internal Medicine; Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetrospective StudieRisk FactorsInternal medicineEpidemiologymedicineInternal MedicineHumansHyperuricemiaRisk factoreducationRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseCardiovascular diseasePrognosisUric AcidchemistryItalyCardiovascular DiseasesResearch DesignUric acidCardiovascular disease; Epidemiology; Uric acidbusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersHumanHigh blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension
researchProduct

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

2008

The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C virus (HCV) infection is probably underestimated because of the increasing spread of this virus worldwide, especially in developing countries. In these patients, anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy may aggravate hepatitis and increase viremia. We evaluated the safety of these treatments, which remain controversial.Thirty-one HCV-positive patients (23 women, 8 men, mean age 59+/-13 yrs, mean disease duration 13+/-11.5 SD yrs) with active RA [Disease Activity Score 28 (DAS28)3.2] unresponsive to conventional therapies were treated with TNF-alpha blockers (infliximab 11, etanercept 17, adalimumab 3) at…

AdultAged 80 and overMalerheumatoid arthritissafetyhepatitis c virus; rheumatoid arthritis; safety; tumor necrosis factor-α blockerTumor Necrosis Factor-alphaAdalimumabHepatitis C ChronicMiddle AgedViral Loadhepatitis c virusInfliximabEtanerceptArthritis Rheumatoidtumor necrosis factor-α blockerAdalimumab Etanercept InfliximabAntirheumatic AgentsHumansFemaleanti-tumor necrosis factor-alpha; rheumatoid arthritis; hepatitis CAgedFollow-Up StudiesRetrospective Studies
researchProduct

Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project

2021

Abstract Background Hyperuricemia is commonly observed in patients with chronic kidney disease (CKD). However, a better understanding of the relationship among uric acid (UA) values, glomerular filtration rate (GFR) and albuminuria may shed light on the mechanisms underlying the excess of cardiovascular mortality associated with both chronic kidney disease and hyperuricemia and lead to better risk stratification. Our main goal was to study the relationships between serum uric acid and kidney disease measures (namely estimated GFR [eGFR] and albuminuria) in a large cohort of individuals at cardiovascular risk from the URic acid Right for heArt Health (URRAH) Project database. Methods Clinica…

NephrologyAdultMalemedicine.medical_specialtySettore MED/09 - Medicina Interna030232 urology & nephrologyAllopurinolRenal functionHyperuricemia030204 cardiovascular system & hematologyKidneyurologic and male genital diseasesGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineSerum uric acidRisk FactorsInternal medicineDiabetes mellitusmedicineeGFRHumansAlbuminuriaHyperuricemiaRenal Insufficiency ChronicAgedbusiness.industryAlbuminuria; Cardiovascular risk; Serum uric acid; eGFRnutritional and metabolic diseaseseGFR.Middle Agedmedicine.diseaseCardiovascular riskUric AcidchemistryNephrologyAlbuminuriaUric acidAlbuminuria; Cardiovascular risk; eGFR; Serum uric acidOriginal ArticleFemalemedicine.symptombusinessmedicine.drugKidney diseaseGlomerular Filtration Rate
researchProduct

Serum uric acid and fatal myocardial infarction: Detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study

2019

Supplemental Digital Content is available in the text

AdultMalemedicine.medical_specialtyAdolescentPhysiologycut-off value030204 cardiovascular system & hematology03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicineuric acidInternal medicineInternal MedicinemedicineORIGINAL PAPERS: EpidemiologyHumanssex030212 general & internal medicineHyperuricemiaMyocardial infarctionRisk factorAgedAged 80 and overuric acid cardiovascular arterial hypertensioncut-off value mortality myocardial infarctionsex uric acidProportional hazards modelbusiness.industrycut-off value mortality myocardial infarction sex uric acidHazard ratioMiddle Agedmedicine.diseasePrognosismortalityConfidence intervalUric acid myocardial infarction epidemiologymyocardial infarctionchemistryItalyHypertensionComputingMethodologies_DOCUMENTANDTEXTPROCESSINGcut-off value; mortality; myocardial infarction; sex; uric acidUric acidFemaleCardiology and Cardiovascular MedicinebusinessCohort study
researchProduct

Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study.

2014

none 330 Women live longer and outnumber men. On the other hand, older women develop more chronic diseases and conditions such as arthritis, osteoporosis and depression, leading to a greater number of years of living with disabilities. The aim of this study was to describe whether or not there are gender differences in the demographic profile, disease distribution and outcome in a population of hospitalized elderly people.Retrospective observational study including all patients recruited for the REPOSI study in the year 2010. Analyses are referred to the whole group and gender categorization was applied.A total of 1380 hospitalized elderly subjects, 50.5\% women and 49.5\% men, were conside…

GerontologyMaleActivities of daily livingSettore MED/09 - Medicina InternaGeriatric MedicineComorbidityDisease distribution; Elderly; Sex-gender difference; In-hospital mortalityDisease distribution; Elderly; In-hospital mortalityElderlyRetrospective StudieDisease distributionActivities of Daily Livinggender80 and overDepression (differential diagnoses)Aged 80 and overeducation.field_of_studyhospitalized elderlyDepressionMortality rateMedicine (all)gender hospitalization elderlyHospitalizationIn-hospital mortalityItalyoutcomeGeriatric Depression ScaleFemaleInpatientHumanPopulationGender-differencesex-gender differencesFollow-Up StudieCognition DisorderDisease distributionmedicineInternal MedicineDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged; 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineHumansDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal MedicineSex DistributioneducationGeriatric AssessmentSex-gender differenceAgedRetrospective StudiesInpatientsbusiness.industrySettore MED/09 - MEDICINA INTERNARetrospective cohort studymedicine.diseaseComorbidityGender-differences; disease distribution; outcome; hospitalized elderlyIn-hospital mortalityElderlyMood disordersChronic DiseaseDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatientsdisease distribution; elderly; in-hospital mortality; sex-gender differencesMorbiditybusinessDisease distribution; Elderly; In-hospital mortality; Sex-gender difference; Aged; Aged 80 and over; Chronic Disease; Cognition Disorders; Comorbidity; Depression; Female; Follow-Up Studies; Geriatric Assessment; Hospitalization; Humans; Italy; Male; Morbidity; Retrospective Studies; Sex Distribution; Activities of Daily Living; Inpatients; Internal Medicine; Medicine (all)Cognition DisordersFollow-Up Studies
researchProduct

The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk

2021

Abstract Introduction Serum uric acid (SUA) has been depicted as a contributory causal factor in metabolic syndrome (MS), which in turn, portends unfavourable prognosis. Aim We assessed the prognostic role of SUA in patients with and without MS. Methods We used data from the multicentre Uric Acid Right for Heart Health study and considered cardiovascular mortality (CVM) as death due to fatal myocardial infarction, stroke, sudden cardiac death, or heart failure. Results A total of 9589 subjects (median age 58.5 years, 45% males) were included in the analysis, and 5100 (53%) patients had a final diagnosis of MS. After a median follow-up of 142 months, we observed 558 events. Using a previousl…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaCardiovascular mortalityPrognosiSudden cardiac deathchemistry.chemical_compoundSerum uric acidRisk FactorsInternal medicineCause of DeathmedicineHumansSerum uric acid.Myocardial infarctionCardiovascular mortality; Metabolic syndrome; Prognosis; Serum uric acidStrokeRetrospective StudiesOriginal Paperbusiness.industryProportional hazards modelHazard ratioGeneral MedicineMiddle Agedmedicine.diseasePrognosisMetabolic syndromeUric AcidSurvival RatechemistryItalyCardiovascular DiseasesHeart failureCardiologyUric acidFemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessBiomarkersFollow-Up Studies
researchProduct

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side ef…

2007

Objective: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. Methods: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessm…

rheumatoid arthritisMaleConcise ReportArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis Rheumatoidimmune system diseasesImmunology and AllergyHealth Status Indicatorsskin and connective tissue diseasesmedicine.diagnostic_testbiologyAntibodies MonoclonalMiddle AgedC-Reactive ProteinTreatment OutcomeBiologic agents; etanercept; infliximab; infusion reactionRheumatoid arthritisErythrocyte sedimentation rateAntirheumatic AgentsFemalemedicine.drugmusculoskeletal diseasesAdultmedicine.medical_specialtyVisual analogue scaleImmunologyBlood Sedimentationinfusion reactionGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicinemedicineHumansAdverse effectRetrospective StudiesChi-Square Distributionbusiness.industryTumor Necrosis Factor-alphaC-reactive proteinetanercept; infliximab; rheumatoid arthritismedicine.diseaseInfliximabInfliximabSurgeryBiologic agentsstomatognathic diseasesImmunoglobulin Gbiology.proteinbusinessinfliximabetanercept
researchProduct